FDA grants accelerated approval to Nuvalent lung cancer drug

The FDA granted accelerated approval to Nuvalent’s Nelkarmi (neladalkib) Nov. 17 for adults with previously treated, locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. The kinase inhibitor is approved for patients who previously received alectinib as their only ALK inhibitor, or at least two ALK inhibitors plus platinum-based chemotherapy, according to […] The post FDA grants accelerated approval to Nuvalent lung cancer drug appeared first...

Original Source

Read the full article at Beckershospitalreview →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.